• Adaptimmune Immunotherapy Increases Time It Takes for Myeloma to Progress, Trial Shows
  • Weighing Myeloma Cells Could Predict Treatment Responses, MIT Study Shows
  • First Myeloma CAR T-cell Therapy Phase 2 Trial Opens Enrollment
  • FDA Allows Trials of Opdivo Combo Therapy to Resume, Signaling No New Safety Concerns
  • Ascentage Gets FDA Nod to Advance APG-1387 into Clinical Trials for Myeloma, Other Cancers
  • CAR T-cells Targeting Integrin β7 Protein Show Promise in Countering Multiple Myeloma Cells
  • First Patient-led Crowdfunding Initiative for Multiple Myeloma Research Tops $500,000 to Fund Two Projects
  • Janssen Seeks US Approval of Darzalex Combo for Newly Diagnosed Multiple Myeloma
  • Adaptive Biotechnologies, Amgen Partner in Phase 3 CANDOR Trial for Multiple Myeloma
  • Janssen Submits New Application to EMA for Darzalex Combo
  • Poseida Developing CAR T-cells to Replace Risky Stem Cell Transplant Pre-treatments
  • Janssen to Share Updates from Darzalex Studies at Hematology Meeting in Atlanta